An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Clinical trial NCT07359066 · RECRUITING
Trial details
- NCT number
- NCT07359066
- Sponsor
- Shanghai SciBrunch Therapeutics Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-08
- Primary completion
- 2028-02-01
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.